Search results
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 36 minutes agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 1 day agoAfter five years, 60% of patients were still alive. Lorbrena-treated patients had an 81% reduced...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 4 hours agoPfizer disclosed on May...
Pfizer, Flagship to focus on obesity drugs under $100M collaboration - Boston Business Journal
The Business Journals· 1 day agoAlmost a year after Cambridge’s Flagship Pioneering and Pfizer Inc. announced a partnership to...
Sarepta Therapeutics gains as Pfizer failure removes overhang By Investing.com
Investing.com· 6 hours agoAmbulatory Assessment (NSAA) and key secondary endpoints, including 10-meter run/walk velocity and...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 1 day agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Flagship taps startup to hunt for obesity drugs that might interest Pfizer
BioPharma Dive via Yahoo Finance· 1 day agoThe venture firm will work with ProFound Therapeutics to “rapidly surface” protein drug candidates...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 10 hours agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 37 minutes agoBiotech stock hit a two-year high in February, but have trended sideways in the months since despite...
Bridgeway Capital Management LLC Boosts Stock Position in Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 10 hours agoBridgeway Capital Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 26.0% during the 4th quarter, according to its most recent 13F filing ...